Bernard Escudier
Active 1991–2026
- 251
- Papers
- 80,716
- Citations
- 121
- h-index
- 248
- i10-index
Citations
Citation sources
Countries
Institutions
Fields
- Medicine57.9%
- Biochemistry, Genetics and Molecular Biology31.1%
- Immunology and Microbiology7.6%
- Engineering0.7%
- Neuroscience0.3%
- Materials Science0.3%
- Other2.1%
Topics
- Cancer Immunotherapy and Biomarkers10%
- Renal cell carcinoma treatment6.3%
- Gut microbiota and health3.8%
- Immunotherapy and Immune Responses3.6%
- Extracellular vesicles in disease3%
- Immune Cell Function and Interaction2.7%
- Other70.6%
Coauthors
- Robert J. Motzer76
- Laurence Albigès57
- Thomas Powles49
- Camillo Porta48
- Toni K. Choueiri48
- Brian I. Rini47
- Alain Ravaud43
- Sylvie Négrier42
- Stéphane Oudard38
- David F. McDermott37
- Christine Chevreau30
- Frede Donskov26
- Yoshihiko Tomita25
- Nizar M. Tannir23
- Saby George23
- Sergio Bracarda23
- Thomas E. Hutson23
- Howard Gurney22
- Cristina Suárez21
- Hans J. Hammers21
- Philippe Barthélémy21
- Cezary Szczylik20
- Frédéric Rolland20
- Marine Gross‐Goupil20
All papers
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
Authors: Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa, Connie P.M. Duong, Maryam Tidjani Alou, Romain Daillère, Aurélie Fluckiger, Meriem Messaoudene, Conrad Rauber, María Paula Roberti, Marine Fidelle, Caroline Flament, Vichnou Poirier-Colame, Paule Opolon, Christophe Klein, Kristina Iribarren, Laura Mondragón, Nicolas Jacquelot, Bo Qu, Gladys Ferrere, Céline Clémenson, Laura Mezquita, J. Remon Masip, Charles Naltet, Solenn Brosseau, Courèche Kaderbhaï, Corentin Richard, Hira Rizvi, Florence Levenez, Nathalie Galleron, Benoît Quinquis, Nicolas Pons, Bernhard Ryffel, Véronique Minard-Colin, Patrick Gonin, Jean‐Charles Soria, Éric Deutsch, Yohann Loriot, François Ghiringhelli, Gérard Zalcman, François Goldwasser, Bernard Escudier, Matthew D. Hellmann, Alexander Eggermont, Didier Raoult, Laurence Albigès, Guido Kroemer, Laurence Zitvogel - Science 2017 cited by 5,594
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Authors: Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier - New England Journal of Medicine 2018 cited by 4,643
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Authors: Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma - New England Journal of Medicine 2015 cited by 5,890
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Authors: Toni K. Choueiri, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Bogdan Żurawski, Víctor Manuel Oyervides-Juárez, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Jeffrey C. Goh, Carlos H. Barrios, Martin Eduardo Richardet, Camillo Porta, Rubén Dario Kowalyszyn, Juan P. Feregrino, Jakub Żołnierek, David Pook, Elizabeth R. Kessler, Yoshihiko Tomita, Ryuichi Mizuno, Jens Bedke, Joshua Zhang, Matthew Maurer, Burçin Şimşek, Flavia Ejzykowicz, Gisela Schwab, Andrea B. Apolo, Robert J. Motzer - New England Journal of Medicine 2021 cited by 1,746
- Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Authors: Bernard Escudier, Thierry Dorval, Nathalie Chaput, Fabrice André, Marie-Pierre Caby, Sophie Novault, Caroline Flament, Christophe Leboulaire, Christophe Borg, Sebastián Amigorena, C Boccaccio, Christian Bonnerot, Olivier Dhellin, Mojgan Movassagh, Sophie Piperno, Caroline Robert, Vincent Serra, Nancy Valente, Jean‐Bernard Le Pecq, Alan Spatz, Olivier Lantz, Thomas Tursz, Eric Angevin, Laurence Zitvogel - Journal of Translational Medicine 2005 cited by 1,259
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
Authors: David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles - Nature Medicine 2018 cited by 1,250
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Authors: Bernard Escudier, Camillo Porta, Manuela Schmidinger, Ferrán Algaba, Jean Jacques Patard, Vincent Khoo, Timothy Eisen, Alan Horwich - Annals of Oncology 2014 cited by 2,259
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Authors: Bernard Escudier, Camillo Porta, Manuela Schmidinger, Nathalie Rioux‐Leclercq, Axel Bex, Vincent Khoo, Viktor Grünwald, Silke Gillessen, Alan Horwich - Annals of Oncology 2019 cited by 1,159
- Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
Authors: Lisa Derosa, Matthew D. Hellmann, Marco Spaziano, Darragh Halpenny, Marine Fidelle, Hira Rizvi, Niamh M. Long, Andrew J. Plodkowski, Kathryn C. Arbour, Jamie E. Chaft, J.A. Rouche, Laurence Zitvogel, Gérard Zalcman, Laurence Albigès, Bernard Escudier, Bertrand Routy - Annals of Oncology 2018 cited by 871
- Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage
Authors: Aurélie Fluckiger, Romain Daillère, Mohamed Sassi, Barbara S. Sixt, Peng Liu, Friedemann Loos, Corentin Richard, Catherine Rabu, Maryam Tidjani Alou, Anne‐Gaëlle Goubet, Fabien Lemaître, Gladys Ferrere, Lisa Derosa, Connie P.M. Duong, Meriem Messaoudene, Andréanne Gagné, Philippe Joubert, Luisa De Sordi, Laurent Debarbieux, Sylvain Simon, Clara‐Maria Scarlata, Maha Ayyoub, Belinda Palermo, Francesco Facciolo, Romain Boidot, Richard Wheeler, Ivo G. Boneca, Zsófia Sztupinszki, Krisztián Papp, István Csabai, Edoardo Pasolli, Nicola Segata, Carlos López-Otı́n, Zoltán Szállási, Fabrice André, Valerio Iebba, Valentin Quiniou, David Klatzmann, Jacques Bou Khalil, S. Khelaifia, Didier Raoult, Laurence Albigès, Bernard Escudier, Alexander Eggermont, Fathia Mami‐Chouaib, Paola Nisticò, François Ghiringhelli, Bertrand Routy, Nathalie Labarrière, Vincent Cattoir, Guido Kroemer, Laurence Zitvogel - Science 2020 cited by 384
- Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Authors: Robert J. Motzer, Romain Banchereau, Habib Hamidi, Thomas Powles, David F. McDermott, Michael B. Atkins, Bernard Escudier, Lifen Liu, Ning Leng, Alexander R. Abbas, Jinzhen Fan, Hartmut Koeppen, Jennifer Lin, Susheela Carroll, Kenji Hashimoto, Sanjeev Mariathasan, Marjorie Green, Darren Tayama, Priti S. Hegde, Christina Schiff, Mahrukh Huseni, Brian I. Rini - Cancer Cell 2020 cited by 561
- Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients
Authors: Lisa Derosa, Bertrand Routy, Marine Fidelle, Valerio Iebba, Laurie Alla, Edoardo Pasolli, Nicola Segata, Aude Desnoyer, Filippo Pietrantonio, Gladys Ferrere, Jean‐Eudes Fahrner, Emmanuelle Le Chatellier, Nicolas Pons, Nathalie Galleron, Hugo Roume, Connie P.M. Duong, Laura Mondragón, Kristina Iribarren, Mélodie Bonvalet, Safae Terrisse, Conrad Rauber, Anne‐Gaëlle Goubet, Romain Daillère, Fabien Lemaître, Anna Reni, Beatrice Casu, Maryam Tidjani Alou, Carolina Alves Costa Silva, Didier Raoult, Karim Fizazi, Bernard Escudier, Guido Kroemer, Laurence Albigès, Laurence Zitvogel - European Urology 2020 cited by 377
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
Authors: Brian I. Rini, Thomas Powles, Michael B. Atkins, Bernard Escudier, David F. McDermott, Cristina Suárez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Jae‐Lyun Lee, Robert D. Hawkins, Alain Ravaud, B. Yа. Alekseev, Michael Staehler, Motohide Uemura, Ugo De Giorgi, Begoña Mellado, Camillo Porta, Bohuslav Melichar, Howard Gurney, Jens Bedke, Toni K. Choueiri, Francis Parnis, Tarik Khaznadar, Alpa Thobhani, Shi Li, Elisabeth Piault‐Louis, Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C. Green, Robert J. Motzer - The Lancet 2019 cited by 1,010
- Renal cell carcinoma
Authors: Brian I. Rini, Steven C. Campbell, Bernard Escudier - The Lancet 2009 cited by 1,633
- Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome
Authors: Lisa Derosa, Valerio Iebba, Carolina Alves Costa Silva, Gianmarco Piccinno, Guojun Wu, Leonardo Lordello, Bertrand Routy, Naisi Zhao, Cassandra Thélémaque, Roxanne Birebent, Federica Marmorino, Marine Fidelle, Meriem Messaoudene, Andrew Maltez Thomas, Gérard Zalcman, S. Friard, Julien Mazières, Clarisse Audigier-Valette, Denis Moro‐Sibilot, François Goldwasser, Arnaud Scherpereel, Hervé Pegliasco, François Ghiringhelli, Nicole Bouchard, Cissé Sow, Ines Darik, Silvia Zoppi, Pierre Ly, Anna Reni, Romain Daillère, Éric Deutsch, Karla A. Lee, Laura A. Bolte, Johannes R. Björk, Rinse K. Weersma, Fabrice Barlési, Lucas Padilha, Ana Finzel, Morten L. Isaksen, Bernard Escudier, Laurence Albigès, David Planchard, Fabrice André, Chiara Cremolini, Stéphanie Martinez, Benjamin Besse, Liping Zhao, Nicola Segata, Jérôme Wojcik, Guido Kroemer, Laurence Zitvogel - Cell 2024 cited by 181
- Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Authors: Robert J. Motzer, David F. McDermott, Bernard Escudier, Mauricio Burotto, Toni K. Choueiri, Hans J. Hammers, Philippe Barthélémy, Elizabeth R. Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Howard Gurney, Christian Kollmannsberger, Marc‐Oliver Grimm, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I. Rini, M. Brent McHenry, Chung‐Wei Lee, Jennifer L. McCarthy, Flavia Ejzykowicz, Nizar M. Tannir - Cancer 2022 cited by 263
- Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
Authors: Robert J. Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher Hocking, Elizabeth R. Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burçin Şimşek, Christian Scheffold, Andrea B. Apolo, Toni K. Choueiri - The Lancet Oncology 2022 cited by 307
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Authors: Robert J. Motzer, Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S. Tykodi, Philippe Barthélémy, Raya Leibowitz‐Amit, Elizabeth R. Plimack, Sjoukje F. Oosting, Bruce G. Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K. Choueiri, Frede Donskov, Marc‐Oliver Grimm, Howard Gurney, Daniel Y.C. Heng, Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 cited by 780
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Authors: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae‐Lyun Lee, Daniel Y.C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N. Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E. Hutson, Sumanta K. Pal, Robert J. Motzer - The Lancet Oncology 2016 cited by 939
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Authors: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Paul N. Mainwaring, Brian I. Rini, Frede Donskov, Hans J. Hammers, Thomas E. Hutson, Jae‐Lyun Lee, Katriina Peltola, Bruce J. Roth, Georg A. Bjarnason, Lajos Géczi, Bhumsuk Keam, Pablo Maroto, Daniel Y.C. Heng, Manuela Schmidinger, Philip W. Kantoff, Anne E. Borgman-Hagey, Colin Hessel, Christian Scheffold, Gisela Schwab, Nizar M. Tannir, Robert J. Motzer - New England Journal of Medicine 2015 cited by 1,226
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Authors: Arnaud Méjean, Alain Ravaud, Simon Thézenas, Sandra Colas, Jean‐Baptiste Beauval, Karim Bensalah, Lionnel Geoffrois, Antoine Thiery-Vuillemin, Luc Cormier, Hervé Lang, Laurent Guy, Gwénaëlle Gravis, Frédéric Rolland, Claude Linassier, É. Lechevallier, Christian Beisland, Michael Aitchison, Stéphane Oudard, Jean‐Jacques Patard, C Théodore, Christine Chevreau, Brigitte Laguerre, Jacques Hubert, Marine Gross‐Goupil, Jean‐Christophe Bernhard, Laurence Albigès, Marc‐Olivier Timsit, Thierry Lebrét, Bernard Escudier - New England Journal of Medicine 2018 cited by 940
- Malignant effusions and immunogenic tumour-derived exosomes
Authors: Fabrice André, Noël E.C. Schartz, Mojgan Movassagh, Caroline Flament, Patricia Pautier, Philippe Morice, Christophe Pomel, Catherine Lhommé, Bernard Escudier, Thierry Le Chevalier, Thomas Tursz, Sebastián Amigorena, Graça Raposo, Eric Angevin, Laurence Zitvogel - The Lancet 2002 cited by 940
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
Authors: Robert J. Motzer, Bernard Escudier, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Elizabeth R. Plimack, Giuseppe Procopio, David F. McDermott, Daniel Castellano, Toni K. Choueiri, Frede Donskov, Howard Gurney, Stéphane Oudard, Martin Eduardo Richardet, Katriina Peltola, Ajjai Alva, Michael A. Carducci, John Wagstaff, Christine Chevreau, Satoshi Fukasawa, Yoshihiko Tomita, Thomas Gauler, Christian Kollmannsberger, Fabio A.B. Schutz, James Larkin, David Cella, M. Brent McHenry, Shruti Shally Saggi, Nizar M. Tannir - Cancer 2020 cited by 337
- Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma
Authors: Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola Jane Lawrence, Robert J. Motzer, Bradley A. McGregor, Richard J. Lee, Rohit Jain, Nancy B. Davis, Leonard J. Appleman, Oscar Goodman, Walter M. Stadler, Sunil Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begoña Mellado, Juan Manuel Sepúlveda-Sánchez, Robert A. Figlin, Thomas Powles, Lalith Akella, Keith Orford, Bernard Escudier - JAMA Oncology 2022 cited by 142
